Peter Smith

Director/Board Member at RYVU THERAPEUTICS S.A.

Health Technology

Consumer Services

Finance

Profile

Dr. Peter Smith is an Advisor at Atlas Venture Advisors, Inc., a Chief Scientific Officer at Amplify Medicines, Inc. and a President & Chief Executive Officer at Remix Therapeutics, Inc. He is on the Board of Directors at Ryvu Therapeutics SA. Dr. Smith was previously employed as a Chief Scientific Officer by H3 Biomedicine, Inc. He received his undergraduate degree from the University of Sheffield Medical School and a doctorate degree from Newcastle University.

Peter Smith active positions

Companies	Position	Start
RYVU THERAPEUTICS S.A.	Director/Board Member	2023-06-13
Remix Therapeutics, Inc. Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA.	Chief Executive Officer	2021-08-16
Atlas Venture Advisors, Inc. Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.	Consultant / Advisor	2017-12-31
Amplify Medicines, Inc. Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith.	Founder	-

All active positions of Peter Smith

Former positions of Peter Smith

Companies	Position	End
H3 Biomedicine, Inc. H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.	Corporate Officer/Principal	2018-12-30

See the detail of Peter Smith's experience

Training of Peter Smith

Newcastle University	Doctorate Degree
University of Sheffield Medical School	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Smith's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
RYVU THERAPEUTICS S.A.	Health Technology

Private companies	4
Remix Therapeutics, Inc. Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA.	Health Technology
Atlas Venture Advisors, Inc. Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.	Finance
Amplify Medicines, Inc. Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith.	Health Technology
H3 Biomedicine, Inc. H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.	Health Technology

See company connections